Hence, cediranib treatment by inhibiting pan-VEGFR, PDGFR, and FGFR may have a greater effect on tumours with a stromal vessel phenotype than treatment with a highly selective VEGFR2-signalling inhibitor such as DC101. Here, KDR is linked to neoplasm.